Research output per year
Research output per year
Personal profile
Research interests
Novel therapies and outcome measures for cystic fibrosis.
Clinical interests
Adult patients with cystic fibrosis clinical outcomes. obstructive lung disease, COPD, pulmonary medicine.
Fingerprint
Dive into the research topics where Daniel Rosenbluth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Update on the Role of Chest Imaging in Cystic Fibrosis
Bugenhagen, S. M., Grant, J. C. E., Rosenbluth, D. B. & Bhalla, S., Sep 2024, In: Radiographics. 44, 9, e240008.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
SIMPLIFY Study Group, Apr 2023, In: The Lancet Respiratory Medicine. 11, 4, p. 329-340 12 p.Research output: Contribution to journal › Article › peer-review
Open Access90 Scopus citations -
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials
VX18-121-101, VX18-561-101 Study Groups, Rubenstein, R. C. & Rosenbluth, D. B., Jun 2023, In: The Lancet Respiratory Medicine. 11, 6, p. 550-562 13 p.Research output: Contribution to journal › Article › peer-review
Open Access41 Scopus citations -
Evaluating the impact of stopping chronic therapies after modulator drug therapy in cystic fibrosis: The SIMPLIFY clinical trial study design
Mayer-Hamblett, N., Nichols, D. P., Odem-Davis, K., Riekert, K. A., Sawicki, G. S., Donaldson, S. H., Ratjen, F., Konstan, M. W., Simon, N., Rosenbluth, D. B., Retsch-Bogart, G., Clancy, J. P., Van Dalfsen, J. M., Buckingham, R. & Gifford, A. H., Aug 2021, In: Annals of the American Thoracic Society. 18, 8, p. 1397-1405 9 p.Research output: Contribution to journal › Article › peer-review
Open Access50 Scopus citations -
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study
VX14-661-110 study group, Jul 2021, In: The Lancet Respiratory Medicine. 9, 7, p. 733-746 14 p.Research output: Contribution to journal › Article › peer-review
Open Access41 Scopus citations